Study on clinical effect of Shugan Shipi Pill combined with entecavir in treating liver depression and spleen deficiency syndrome in compensatory stage of hepatitis B cirrhosis
Objective To investigate the clinical therapeutic effect,liver function indexes and adverse reactions of Shugan Shipi Pill combined with entecavir in the treatment of liver depression and spleen deficiency syndrome in the compensatory stage of hepatitis B cirrhosis.Methods A total of 60 patients with liver depression and spleen deficiency syndrome at the compensatory stage of hepatitis B cirrhosis were randomly divided into a control group and a study group,with 30 cases in each group.The control group received entecavir alone for treatment,and the study group received Shugan Shipi Pill combined with entecavir for treatment.The therapeutic effect,liver function indexes[total bilirubin(TBil),aspartate aminotransferase(AST),albumin(ALB)]and adverse reactions were compared between the two groups.Results The clinical therapeutic effect of 96.7％in the study group was higher than that of 70.0％in the control group(P<0.05).After treatment,TBil of(18.0±3.5)μmol/L and AST of(32.4±4.2)U/L in the study group were lower than those of(21.9±4.2)μmol/L and(40.5±6.9)U/L in the control group;and ALB of(42.7±5.0)g/L was higher than that of(36.9±6.0)g/L in the control group(P<0.05).The incidence of adverse reactions of 3.3％in the study group was lower than that of 23.3％in the control group(P<0.05).Conclusion In the treatment of liver depression and spleen deficiency syndrome during the compensatory stage of hepatitis B cirrhosis,Shugan Shipi Pill combined with entecavir can effectively optimize various liver function indexes,reduce the incidence of adverse reactions,and improve clinical safety,with significant effects.
Shugan Shipi PillEntecavirHepatitis BCompensatory stage of liver cirrhosisLiver depression and spleen deficiency syndromeLiver function indexAdverse reactions
万方数据
维普
